Several analysts working at Wall Street have already pushed out forecasts that the stocks of CERS would be reporting an EPS of $0.09 for the current quarter. None of the analysts actually issued any particular estimate into the earnings. The company reportedly put up an EPS of $0.10 the previous year, which was indicative of an annual growth rate of 10%. CERS will be uploading its next quarterly report on the 4th of May.
The Quarterly Estimates of CERS
The stocks of CERS previously updated their quarterly report last Thursday. The company dealing in biotechnology had an EPS which was reported at around $0.09 for the current quarter, which missed out on the consensus estimate laid down by Zacks at around $0.08. The net margin of the company stood at -73.72%, with a return on equity which was set at -63.47%.
Zacks Investment Research also reduced the shares of the company from a rating of hold to a rating of sell in a 19th February research report.
The stocks of CERS traded on Friday at $6.14. The year low of the company has been set at $2.71, while the year high is at $8.87. The market cap of the firm is $1.03 billion, with a -15.74 PE ratio, and a 1.37 beta. The debt-to-equity ratio of the company is 0.36, while the company also enjoys a 3.84 current ratio. The moving average price of the company over a course of 50 days is $7.27.
Chrystal Menard, one of the insiders in the business reportedly sold around 41,636 shares of CERS in a transaction that took place on the 11th of December. The average price per stock was $8 with the total valuation coming in at $330,904.
